Skip to main content

Table 2 High Levels of T Effector (CD4+, CD8+) and CD56+ NK Cells in Pre-NAC (a) ALN(b) Metastatic Tumours: Association with a PCR Following NAC

From: Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

Lymphocyte Subsets (n = 20) Groups Tumour Infiltration Median (range)(c) P Value(d)(PCR Versus Non PCR)
CD4+ Pathological Complete Response (PCR, n = 9) 65.0 (19.4-157.4) 0.004e
Non Pathological Complete Response (Non PCR, n = 11) 13.2 (0.6-100.8)
CD8+ Pathological Complete Response (PCR, n = 9) 99.2 (33.2-160.8) 0.001e
Non Pathological Complete Response (Non PCR, n = 11) 11.6 (0.4-93.0)
FOXP3+ Pathological Complete Response (PCR, n = 9) 18.0 (5.0-73.6) 0.152
Non Pathological Complete Response (Non PCR, n = 11) 6.4 (1.0-20.4)
CTLA-4+ Pathological Complete Response (PCR, n = 9) 2.6 (0.4-11.6) 0.112
Non Pathological Complete Response (Non PCR, n = 11) 0.8 (0.0-2.2)
CD56+ Pathological Complete Response (PCR, n = 9) 2.2 (1.0-26.8) 0.010e
Non Pathological Complete Response (Non PCR, n = 11) 1.0 (0.0-2.2)
  1. (a)NAC: Neoadjuvant chemotherapy; (b) ALN: Axillary lymph node; (c) Average cell count per 400× high-power field (see Materials and Methods); (d) Mann-Whitney U test; e Statistically significant
Back to article page